FDA misses PDUFA review deadline for Agios’ thalassemia drugnews2025-12-08T18:08:34+00:00December 8th, 2025|Endpoints News|
Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approvalnews2025-12-08T16:25:42+00:00December 8th, 2025|Endpoints News|
BioNTech, OncoC4’s antibody more than halves risk of death in Phase 3 lung cancer trialnews2025-12-08T16:14:27+00:00December 8th, 2025|Endpoints News|
Cogent’s mastocytosis drug continues momentum, helps treat sicker patientsnews2025-12-08T15:51:47+00:00December 8th, 2025|Endpoints News|
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPACnews2025-12-08T15:50:56+00:00December 8th, 2025|Endpoints News|
#ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AMLnews2025-12-08T15:45:18+00:00December 8th, 2025|Endpoints News|
Merck outbid three competitors in Cidara acquisition — new filingnews2025-12-08T14:41:45+00:00December 8th, 2025|Endpoints News|
Updated: Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early resultsnews2025-12-08T14:04:26+00:00December 8th, 2025|Endpoints News|
Mirum to pay $620M for Bluejay and its hepatitis D antibodynews2025-12-08T13:00:20+00:00December 8th, 2025|Endpoints News|
Updated: Wave Life Sciences’ RNA obesity shot cuts fat and retains muscle, but appears to lag behind Lilly’s for nownews2025-12-08T12:30:29+00:00December 8th, 2025|Endpoints News|
